MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): A randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

Antonio Uccelli, Alice Laroni, Lou Brundin, Michel Clanet, Oscar Fernandez, Seyed Massood Nabavi, Paolo A. Muraro, Roberto S. Oliveri, Ernst W. Radue, Johann Sellner, Per Soelberg Sorensen, Maria Pia Sormani, Jens Thomas Wuerfel, Mario A. Battaglia, Mark S. Freedman, Bruno Bonetti, Carolina Rush, Concepción Herrera, Cristina Ramo Tello, David MillerDavid Szwajcer, Dirk Strunk, Donna Wall, Eduardo Aguera-Morales, Eva Rohde, Francesco Dazzi, Giancarlo Comi, Gianvito Martino, Guillermo Izquierdo Ayuso, H. Rabinovitch, Heather MacLean, James Marriott, Juan Racosta, Leila Arab, Mario Gimona, Martino Introna, Morten Blinkenberg, Naser Aghdami, Rehiana Ali, Reza Vosoughi, Richard Nicholas, Ruth Ann Marrie, Shahedeh Karimi

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): A randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis'. Together they form a unique fingerprint.

Medicine & Life Sciences